Though the pathophysiology of clinical obesity is undoubtedly multifaceted, several lines of clinical evidence implicate an important functional role for glucagon-like peptide 1 (GLP-1) signalling. Clinical studies assessing GLP-1 responses in normal weight and obese subjects suggest that weight gain may induce functional deficits in GLP-1 signalling that facilitates maintenance of the obesity ...

This brief review describes the potential non-glycaemic effects and benefits of glucagon like peptide 1 receptor agonists (GLP1RA). It lists various indications in which this class of drugs has been used, and explains the rationale behind this use. The potential uses of GLP1RA extend across the entire spectrum of endocrinology and metabolism, from hypothalamic obesity to non-alcoholic steatohep...

OBJECTIVE Continuously administered insulin is limited by the need for frequent blood glucose measurements, dose adjustments, and risk of hypoglycemia. Regimens based on glucagon-like peptide 1 (GLP-1) could represent a less complicated treatment alternative. This alternative might be advantageous in hyperglycemic patients hospitalized for acute critical illnesses, who benefit from near normogl...

OBJECTIVE The aim of this study was to elucidate whether age plays a role in the expansion or regeneration of beta-cell mass. RESEARCH DESIGN AND METHODS We analyzed the capacity of beta-cell expansion in 1.5- and 8-month-old mice in response to a high-fat diet, after short-term treatment with the glucagon-like peptide 1 (GLP-1) analog exendin-4, or after streptozotocin (STZ) administration. ...

In this issue we review recent publications describing: A meta-analysis of 15 trials investigating GLP-1 RAs in combination with basal insulin GLP-1 RA/basal insulin combinations across a wide range of insulin titration The efficacy and safety differences between short-acting (intermittent) versus longeracting (continuous) GLP-1 RAs in combination with basal insulin The effects on glycemic cont...